Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States
Open Access
- 1 September 2011
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 17 (9) , 1591-1598
- https://doi.org/10.3201/eid1709.110295
Abstract
From April 2009 through March 2010, during the pandemic (H1N1) 2009 outbreak, ≈8.2 million prescriptions for influenza neuraminidase-inhibiting antiviral drugs were filled in the United States. We estimated the number of hospitalizations likely averted due to use of these antiviral medications. After adjusting for prescriptions that were used for prophylaxis and personal stockpiles, as well as for patients who did not complete their drug regimen, we estimated the filled prescriptions prevented ≈8,400–12,600 hospitalizations (on the basis of median values). Approximately 60% of these prevented hospitalizations were among adults 18–64 years of age, with the remainder almost equally divided between children 0–17 years of age and adults >65 years of age. Public health officials should consider these estimates an indication of success of treating patients during the 2009 pandemic and a warning of the need for renewed planning to cope with the next pandemic.Keywords
This publication has 23 references indexed in Scilit:
- Effects of Adverse Events on the Projected Population Benefits and Cost-effectiveness of Using Live Attenuated Influenza Vaccine in Children Aged 6 Months to 4 YearsArchives of Pediatrics & Adolescent Medicine, 2011
- High costs of influenza: Direct medical costs of influenza disease in young childrenVaccine, 2010
- Early administration of oral oseltamivir increases the benefits of influenza treatmentJournal of Antimicrobial Chemotherapy, 2002
- Oral oseltamivir treatment of influenza in childrenThe Pediatric Infectious Disease Journal, 2001
- Zanamivir for the Treatment of Influenza A and B Infection in High-Risk PatientsArchives of internal medicine (1960), 2001
- Effect of zanamivir on duration and resolution of influenza symptomsClinical Therapeutics, 2000
- Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trialThe Lancet, 2000
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000
- Cost of treating influenza in emergency department and hospital settings.2000
- Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European StudyJournal of Infection, 2000